vaccines-world-2017-keynote

4 / 7

alliedacademies
Page 12
Virology Research Journal
Volume 1 Issue 4
Notes:
Vaccines World 2017
November 09-10, 2017 Vienna, Austria
21st World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Geert C Mudde, Virol Res J 2017, 1:4
Targeted vaccination and intrinsic adjuvant
function: Next generation checkpoint control
Using the S-TIR™ technology platform for human
specific therapeutic vaccines OncoQR ML has
developed two prototype vaccines for treatment
of pancreatic cancer (TYG100) and breast cancer
(OQR200). Vaccines derived from this platform consist
of 2 modules, the disease specific module, “immunogen”
and the generic module, “warhead”, which directs the
vaccines to CD32 on antigen presenting cells, especially
pDCs and B cells. The immunogen in oncology is a
tumor associate auto-antigen, against which under
normal conditions no Clinically relevant immune
responses can be induced. However, in combination
with the warhead, thanks to intrinsic check point control,
the immune system generates very strong and rapid
antibody and T cell immune responses. The responses
are reversible and boostable, thus allowing fine-tuning
of the clinical responses on a patient to patient basis.
S-TIR™ vaccines in contrast to the current checkpoint
inhibitors do not induce autoimmune disease and are
tumor specific while mobilizing both arms of the immune
system against the tumor.
Biography
Geert CMudde received a PhD in Immunology from theUniversity of Utrecht in 1985
and started his international professional career at the Swiss Institute for Asthma
and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/
biotech industry, where he held several senior management positions at the
Novartis Research Institute in Vienna,Austria, the Parke Davis Research Institute in
Fresnes, France, IngeniumPharmaceuticals, Martinsried, Germany, and at Igeneon
AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as
Interim Manager, he co-founded the biotech company F-star Biotechnology, where
he served as Chief Scientific Officer from 2007 to 2009. In 2009, together with
Christof Langer, he started to develop the S-TIR™ technology platform for human
specific therapeutic vaccines which led to the foundation of S-TARget therapeutics
GmbH in 2010. Since then he serves as CSO and Managing Director for S-TARget
therapeutics as well as for the S-TIR™ technology spin-off companies OncoQR ML
GmbH and TYG oncology Ltd., which were both founded in 2013.
Geert C Mudde
OncoQR ML GmbH, Austria